Acute treatment for neuromyelitis optica in real-world setting
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with NMOSD and have a positive blood test for AQP4 antibodies.
- You are in the middle of a new or worsening attack that started within the last 3 weeks, affecting your vision or spinal cord.
- Your vision in the affected eye has dropped to 20/200 or worse, or your ability to walk has gotten much worse (EDSS score of 6.0 or higher).
- You agree to get a meningococcal vaccine and to receive eculizumab during and for 2 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called sivelestat for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a relapse. The drug may help reduce damage during the relapse and improve recovery.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
This trial tests whether an investigational drug called KSVCBD can safely reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). If you have had at least one relapse in the past year and meet other criteria, you may be able to join.
This study tests whether a low dose of a protein called IL-2 can safely help control the immune system in people with neuromyelitis optica spectrum disorder (NMOSD). It aims to reduce disease activity and improve symptoms.
Hear when a new Neuromyelitis Optica Spectrum Disorder Attack trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.